{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["88(3)"],"submitter":["Doyle EB"],"pubmed_abstract":["<h4>Aims</h4>To assess the potential of interleukin-6 (IL-6) signalling blockade in the lung to treat SARS-CoV-2 infection via model-based simulation by exploring soluble IL-6 receptor (sIL-6R) sequestration by tocilizumab (TCZ) and IL-6 sequestration by siltuximab (SIL).<h4>Methods</h4>Literature values of IL-6, IL-6 antagonist SIL, sIL-6R, IL-6R antagonist TCZ and their respective binding constants were used to develop a model to predict the impact of treatment on IL-6 signalling. Models were used to generate simulated bronchoalveolar lavage fluid concentrations for normal subjects, subjects at risk of developing acute respiratory distress syndrome (ARDS), and subjects with ARDS under 4 conditions: without treatment; treatment with TCZ; treatment with SIL; and treatment with TCZ + SIL.<h"],"journal":["British journal of clinical pharmacology"],"pagination":["1043-1053"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8444890"],"repository":["biostudies-literature"],"pubmed_title":["COVID-19 acute respiratory distress syndrome: A simulation study of the effects of combination therapy with tocilizumab and siltuximab."],"pmcid":["PMC8444890"],"pubmed_authors":["Bentley D","Doyle EB","Dodds MG"],"additional_accession":[]},"is_claimable":false,"name":"COVID-19 acute respiratory distress syndrome: A simulation study of the effects of combination therapy with tocilizumab and siltuximab.","description":"<h4>Aims</h4>To assess the potential of interleukin-6 (IL-6) signalling blockade in the lung to treat SARS-CoV-2 infection via model-based simulation by exploring soluble IL-6 receptor (sIL-6R) sequestration by tocilizumab (TCZ) and IL-6 sequestration by siltuximab (SIL).<h4>Methods</h4>Literature values of IL-6, IL-6 antagonist SIL, sIL-6R, IL-6R antagonist TCZ and their respective binding constants were used to develop a model to predict the impact of treatment on IL-6 signalling. Models were used to generate simulated bronchoalveolar lavage fluid concentrations for normal subjects, subjects at risk of developing acute respiratory distress syndrome (ARDS), and subjects with ARDS under 4 conditions: without treatment; treatment with TCZ; treatment with SIL; and treatment with TCZ + SIL.<h","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-06-01T00:57:00.405Z","creation":"2025-06-01T00:57:00.405Z"},"accession":"S-EPMC8444890","cross_references":{"pubmed":["34318516"],"doi":["10.1111/bcp.15009"]}}